Subscribe
shutterstock_1349461187_pavel_kapysh
Pavel Kapysh / Shutterstock.com
16 December 2021AmericasAlex Baldwin

Intubated patients sedative patent the focus of ACS Dobfar suit

Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FTC approves Sun Pharma’s $4bn Ranbaxy merger
2 February 2015   The US Federal Trade Commission has given the green light for Sun Pharmaceutical to merge with Indian generic drug maker Ranbaxy for $4 billion.
Big Pharma
Court denies Sun Pharma’s bid to avoid trial
25 November 2021   Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
FTC approves Sun Pharma’s $4bn Ranbaxy merger
2 February 2015   The US Federal Trade Commission has given the green light for Sun Pharmaceutical to merge with Indian generic drug maker Ranbaxy for $4 billion.
Big Pharma
Court denies Sun Pharma’s bid to avoid trial
25 November 2021   Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.

More on this story

Americas
FTC approves Sun Pharma’s $4bn Ranbaxy merger
2 February 2015   The US Federal Trade Commission has given the green light for Sun Pharmaceutical to merge with Indian generic drug maker Ranbaxy for $4 billion.
Big Pharma
Court denies Sun Pharma’s bid to avoid trial
25 November 2021   Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?